B-cell-depleting agents (for example, rituximab) | High risk (>10%) | Yes |
|
Anthracycline-derived chemotherapy (for example, doxorubicin, epirubicin) | High risk (>10%) | Yes |
|
Systemic corticosteroid therapy ≥4 weeks at a dose ≥10 mg prednisoloneb | Moderate risk (1–10%) | Yes |
|
TNF- α inhibitors (for example, etanercept, infliximab, adalimumab) | Moderate risk (1–10%) | Yes |
Cytokine and integrin inhibitors (for example, natalizumab, abatacept) | | |
Tyrosine kinase inhibitors (for example, imatinib) | | |
|
Systemic corticosteroid therapy ≥4 weeks at a dose<10 mg prednisolonea | Low risk (<1%) | No |
|
Traditional immunosupressives, for example, azathioprine, methotrexate, 6-mercaptopurine | Low risk (<1%) | No |